Advertisement

Gastro-News

, Volume 5, Issue 6, pp 48–52 | Cite as

Hepatologie — Teil 6: Hepatitis C

HCV — Eine Erkrankung auf dem — Weg zur Eradikation?

  • Gudrun Hilgard
  • Heiner Wedemeyer
fortbildung

Kaum eine andere Erkrankung hat in den letzten Jahren für so viel öffentliches Interesse gesorgt wie die Hepatitis-C-Virus-Infektion und ihre neuen Therapieoptionen, zu gleichen Teilen wegen ihrer sensationellen Heilungserfolge, aber auch wegen ihrer in der ersten Phase „sensationellen“ Preise. Mittlerweile ist aber vielfach belegt worden, dass die Behandlung der chronischen Hepatitis C in jedem Fall nicht nur Komplikationen der Leberzirrhose verhindert, sondern kosteneffektiv und langfristig sogar kostensparend ist.

Literatur

  1. 1.
    Wedemeyer H et al. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. Liv Int 2017; 37:1468–14752CrossRefGoogle Scholar
  2. 2.
    Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018;5:1178–1187CrossRefGoogle Scholar
  3. 3.
    Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 4: 401–412.CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat 2018 Nov;25 Suppl 3:6–14CrossRefPubMedGoogle Scholar
  6. 6.
    Antidhilfe.de nach Sarrazin C et al. Z Gastroenterol 2010, 48: 289–351CrossRefPubMedGoogle Scholar
  7. 7.
    Epidemiologisches Bulletin, Ausgabe 29/2018, S. 275Google Scholar
  8. 8.
    Zeuzem et al. Dtsch Arztebl Int 2017;114(1-2):11–21PubMedPubMedCentralGoogle Scholar
  9. 9.
    Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H et al. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion“. Z Gastroenterol 2018; 56:756–838CrossRefPubMedGoogle Scholar
  10. 10.
    European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;  https://doi.org/10.1016/j.jhep.2018.03.026Google Scholar
  11. 11.
    Höner zu Siederdissen C, Buggisch P, Böker KHW, Schott E, Klinker H, Pathil A et al. Treatment of Hepatitis C genotype 1 infection in Germany — effectiveness and safety of antiviral treatment in a real world setting. UEG Journal 2018;6:213–224PubMedGoogle Scholar
  12. 12.
    Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 2017;37:205–211CrossRefPubMedGoogle Scholar
  13. 13.
    Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. AP&T 2017;45:688–700Google Scholar
  14. 14.
    Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M et al. Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients: Results from the German Hepatitis C-Registry. Drugs & Aging 2018;35:843–857CrossRefGoogle Scholar
  15. 15.
    Bischoff J, Mauss, Cordes D, Lutz T, Scholten S, Moll A et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Medicine 2018;19:299–307CrossRefPubMedGoogle Scholar
  16. 16.
    Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hep 2018;68:663–671CrossRefGoogle Scholar
  17. 17.
    Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D et al. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology 2018;69:982–984CrossRefPubMedGoogle Scholar
  18. 18.
    Wedemeyer H. Dtsch Arztebl 2018;115:27–28Google Scholar
  19. 19.
    Reese P et al.: Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial, Ann Intern Med. 2018;169(5):273–281CrossRefPubMedGoogle Scholar
  20. 20.
    Willuweit K et al.: Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation. Minerva Gastroenterol Dietol. 2017 Mar;63(1):55–61PubMedGoogle Scholar
  21. 21.
    Polaris Observatory HCV Collaborators: Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–76CrossRefGoogle Scholar
  22. 22.
    Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction 2018;113:868–882CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Gastroenterologie und HepatologieUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations